Neocortix Selects Walt & Company to Manage Launch of First Large-Scale Mobile COVID-19 Viral Protein Structure Research Initiative

CAMPBELL, Calif., July 9, 2020 /PRNewswire/ -- Walt & Company, an award-winning Silicon Valley tech public relations and social media agency, today announced that it has been selected by Neocortix, developers of disruptive Cloud at the Edge virtual data center solutions, to manage the launch of the first-of-its-kind, large-scale mobile research initiative to conduct computational biology experiments and simulations of folding viral proteins¹ to create new therapeutics and diagnostics in the fight against COVID-19.

The Neocortix Cloud Services Platform allows the unused capacity of large numbers of individual mobile phones to be harnessed into a single, unified computational engine. At scale – with potentially tens of millions of phone processors working in unison – Neocortix can deliver analytical performance that equals or surpasses the computing power accessible in today's most advanced supercomputing facilities. Neocortix Cloud at the Edge technology has the power and efficiency to provide scientists with an additional advantage in deploying intricate research and predictive analytics across infinite applications.

"The health of millions of people around the world, and the future of our interconnected global economy, rest on the success of government, academic and corporate scientists working tirelessly to develop COVID-19 vaccines and therapeutics," said Lloyd Watts, founder and CEO, Neocortix. "Our mobile COVID-19 research initiative will provide these professionals with another channel to help fight COVID-19. We selected Walt & Company to manage the announcement because of their expertise and impressive track record in successfully communicating important and complex technologies."

Walt & Company will be providing Neocortix with a range of communications services including leadership positioning, media and analyst relations, partner communications, and editorial services.

"Neocortix's advanced technology platform makes for a compelling story across a wide range of business, vertical market and consumer channels," said Robert Walt, president of Walt & Company. "We're delighted to be working with a company that is at the forefront of data science and mobile technologies, leveraging its integrated platform to battle COVID-19."

About Neocortix
Headquartered in Santa Clara, Calif., Neocortix was founded in 2013. The company's disruptive "Cloud at the Edge" technology benefits anyone who needs cloud services by eliminating the costs associated with big, expensive data centers. Solutions include PhonePaycheck, an Android app that pays users for the use of their smartphone while they are not using it, and Neocortix Cloud Services, a distributed Cloud Computing Service running on a worldwide network of mobile devices. Please visit www.neocortix.com for more information.

About Walt & Company
Walt & Company specializes in developing tech PR and social media programs and campaigns that advance its clients' marketing and corporate agendas by generating actionable awareness in all influential formats and forums. For more than 25 years, when it comes to building corporate credibility, product awareness and brand recognition, Walt & Company has its clients covered. For further information, visit www.walt.com.

¹ Protein folding is the physical process by which a protein chain acquires its native 3-dimensional structure, a conformation that is usually biologically functional, in an expeditious and reproducible manner. It is the physical process by which a polypeptide folds into its characteristic and functional three-dimensional structure from a random coil. Wikipedia, July 2020

Product and brand names are trademarks and/or registered trademarks of their respective companies. Walt & Company disclaims any and all rights in these marks.

View original content to download multimedia:http://www.prnewswire.com/news-releases/neocortix-selects-walt--company-to-manage-launch-of-first-large-scale-mobile-covid-19-viral-protein-structure-research-initiative-301090791.html

SOURCE Walt & Company